Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 7/20 | 0.49 |
| ▸ | GABRG2 | P18507 | 7/20 | 0.49 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.49 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.49 |
| ▸ | GABRA3 | P34903 | 7/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.49 |
| ▸ | GABRA4 | P48169 | 7/20 | 0.49 |
| ▸ | GABRA6 | Q16445 | 7/20 | 0.49 |
| ▸ | GABRP | O00591 | 6/20 | 0.49 |
| ▸ | GABRD | O14764 | 6/20 | 0.49 |
| ▸ | GABRB1 | P18505 | 6/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.49 |
| ▸ | GABRE | P78334 | 6/20 | 0.49 |
| ▸ | GABRG1 | Q8N1C3 | 6/20 | 0.49 |
| ▸ | GABRG3 | Q99928 | 6/20 | 0.49 |
| ▸ | GABRQ | Q9UN88 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31285451 | 1.00 | GABRA1 (0.49) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL1019601 | 0.89 | CYP1A2 (0.59) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL1644521 | 0.81 | POLB (0.70) | ALDH1A1KMT2APOLBCYP1A2LMNA | |
| SCHEMBL1644378 | 0.81 | CYP1A2 (0.52) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL1020342 | 0.81 | KDM4E (0.50) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL197360 | 0.80 | CYP1A2 (0.50) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL544241 | 0.79 | MAPK1 (0.52) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL12184767 | 0.79 | POLB (0.46) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL30445565 | 0.79 | POLB (0.46) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL12986652 | 0.79 | GABRA1 (0.47) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098667-A1 | USP30 INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR, AND USE THEREOF | 长春金赛药业有限责任公司 | 2026-05-15 | — | — | WO | disclosed |
| EP-4695252-A1 | IMIDAZO[1,2-A]PYRAZINE DERIVATIVES | Syngenta Crop Protection AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024213659-A1 | IMIDAZO[1,2-A]PYRAZINE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2024-10-17 | — | — | WO | disclosed |
| CN-118684631-A | External nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP 1) inhibitors, compositions and uses thereof | 中国科学院上海药物研究所 | 2024-09-24 | — | — | CN | disclosed |
| CN-113264921-B | Pyrazolyl-ureas as kinase inhibitors | 瑞斯比维特有限公司 | 2024-09-13 | — | — | CN | disclosed |
| US-11724987-B2 | Compositions and methods of treating retinal disease | ALDEYRA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-11724987-B2 | Compositions and methods of treating retinal disease | ALDEYRA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230091047-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-23 | — | — | US | disclosed |
| US-20230041335-A1 | COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASE | ALDEYRA THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
| EP-3938362-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-01-19 | — | — | EP | disclosed |
| EP-2379513-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-10-26 | — | — | EP | disclosed |
| US-7973025-B2 | Compositions and methods of treating retinal disease | NEURON SYSTEMS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| WO-2010078408-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BIOGEN IDEC MA INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| EP-1268443-B1 | 2-HYDROXY-MUTILIN CARBAMATE DERIVATIVES FOR ANTIBACTERIAL USE | SMITHKLINE BEECHAM PLC (GB) | 2009-07-29 | — | — | EP | disclosed |
| US-20090182009-A1 | Compositions and methods of treating retinal disease | NEURON SYSTEMS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-20070135481-A1 | Compositions and methods of treating retinal disease | ALDEYRA THERAPEUTICS, INC. (F/K/A ALDEXA THERAPEUTICS, INC. F/K/A NEURON SYSTEMS, INC.) | 2007-06-14 | — | — | US | disclosed |
| US-6972297-B2 | 2-Hydroxy-mutilin carbamate derivatives for antibacterial use | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-12-06 | — | — | US | disclosed |
| US-20030114674-A1 | 2-Hydroxy-mutilin carbamate derivatives for antibacterial use | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-06-19 | — | — | US | disclosed |
| EP-1268443-A1 | 2-HYDROXY-MUTILIN CARBAMATE DERIVATIVES FOR ANTIBACTERIAL USE | SmithKline Beecham p.l.c. (GB) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001074788-A1 | 2-HYDROXY-MUTILIN CARBAMATE DERIVATIVES FOR ANTIBACTERIAL USE | SMITHKLINE BEECHAM PLC (GB) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114674-A1 | 2-Hydroxy-mutilin carbamate derivatives for antibacterial use | MSH6, MSH2, PMS2 | GABRA1 1266/4885GABRG2 699/4885GABRB3 1550/4885 |
| US-20230041335-A1 | COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASE | ALDH1A2, PLA2G2E, CLN6 | GABRA1 4108/4885GABRG2 3873/4885GABRB3 3144/4885 |
| US-20230091047-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | HAVCR2, HCCS, TYMP | GABRA1 797/4885GABRG2 523/4885GABRB3 233/4885 |
| US-20090182009-A1 | Compositions and methods of treating retinal disease | ALDH1A2, PLA2G2E, CLN6 | GABRA1 4108/4885GABRG2 3873/4885GABRB3 3144/4885 |
| US-11724987-B2 | Compositions and methods of treating retinal disease | ALDH1A2, PLA2G2E, CLN6 | GABRA1 4108/4885GABRG2 3873/4885GABRB3 3144/4885 |
| US-20070135481-A1 | Compositions and methods of treating retinal disease | ALDH1A2, PLA2G2E, CLN6 | GABRA1 4108/4885GABRG2 3873/4885GABRB3 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.